SCHEMBL4283091

SCHEMBL4283091

CCOc1cc(-c2nc(CCC(=O)c3ccccc3OCC)co2)ccc1OC(F)F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCLAT1 Q6UWP7 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
RAB9A P51151 3/20 0.38
PDE4A P27815 2/20 0.38
PDE4B Q07343 2/20 0.38
PDE4C Q08493 2/20 0.38
PDE4D Q08499 2/20 0.38
KDM4E B2RXH2 2/20 0.38
HSD17B10 Q99714 2/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
MAPK1 P28482 2/20 0.37
ABCB1 P08183 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 2/20 0.36
HTT P42858 1/20 0.36
S1PR1 P21453 4/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4275143 0.98 PDE4A (0.40) LCLAT1SMN1; SMN2RAB9APDE4APDE4B
SCHEMBL4281537 0.96 LCLAT1 (0.39) LCLAT1SMN1; SMN2RAB9APDE4APDE4B
SCHEMBL4280844 0.95 PDE4A (0.38) LCLAT1SMN1; SMN2RAB9APDE4APDE4B
SCHEMBL4280745 0.94 PDE4A (0.40) RAB9APDE4APDE4BPDE4CPDE4D
SCHEMBL4285247 0.94 SMN1; SMN2 (0.40) LCLAT1SMN1; SMN2RAB9AKDM4EHSD17B10
SCHEMBL4274922 0.94 SMN1; SMN2 (0.38) LCLAT1SMN1; SMN2PDE4APDE4BPDE4C
SCHEMBL4284521 0.93 PARP1 (0.36) LCLAT1SMN1; SMN2RAB9APDE4APDE4B
SCHEMBL4281241 0.93 LCLAT1 (0.38) LCLAT1SMN1; SMN2RAB9APDE4APDE4B
SCHEMBL4284392 0.93 LCLAT1 (0.38) LCLAT1SMN1; SMN2RAB9AKDM4ENPC1
SCHEMBL4283045 0.93 PDE4D (0.42) PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108497-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICALC., LTD. (JP) 2026-04-23 US disclosed
US-20240148699-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-05-09 US disclosed
US-20220265613-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2022-08-25 US disclosed
US-20200078340-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-03-12 US disclosed
US-20190070151-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-03-07 US disclosed
US-20190070151-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-03-07 US disclosed
US-RE46792-E1 Oxazole compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2018-04-17 US disclosed
US-RE46792-E1 Oxazole compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2018-04-17 US disclosed
US-RE46792-E1 Oxazole compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2018-04-17 US disclosed
US-20170216260-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2017-08-03 US disclosed
US-20170216260-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2017-08-03 US disclosed
US-20170216260-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2017-08-03 US disclosed
EP-1954684-B1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMA CO LTD (JP) 2014-05-07 EP disclosed
US-20140100226-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-04-10 US disclosed
US-8637559-B2 Oxazole compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-01-28 US disclosed
US-8637559-B2 Oxazole compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-01-28 US disclosed
US-8637559-B2 Oxazole compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-01-28 US disclosed
US-20090221586-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-09-03 US disclosed
WO-2007058338-A9 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMA CO LTD (JP) 2007-11-01 WO disclosed
WO-2007058338-A2 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170216260-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A LCLAT1 2111/4885SMN1; SMN2 3069/4885RAB9A 4239/4885
US-20140100226-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A LCLAT1 2111/4885SMN1; SMN2 3069/4885RAB9A 4239/4885
US-20240148699-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A LCLAT1 2111/4885SMN1; SMN2 3069/4885RAB9A 4239/4885
US-20260108497-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE7B, PDE4B, PDE1B LCLAT1 3769/4885SMN1; SMN2 2148/4885RAB9A 2305/4885
US-20090221586-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A LCLAT1 2111/4885SMN1; SMN2 3069/4885RAB9A 4239/4885
US-20200078340-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A LCLAT1 2111/4885SMN1; SMN2 3069/4885RAB9A 4239/4885
US-20220265613-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A LCLAT1 2171/4885SMN1; SMN2 3357/4885RAB9A 4352/4885
US-20190070151-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A LCLAT1 2111/4885SMN1; SMN2 3069/4885RAB9A 4239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.